Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026 at 11:00 a.m. ET. The company is a clinical-stage biopharmaceutical developer targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease. The live webcast is available under the Investors tab on the company website and will be archived for 90 days.

News Market Reaction – ABOS

+0.30%

11 alerts

+0.30% News Effect

+7.6% Peak Tracked

-2.6% Trough Tracked

+$632K Valuation Impact

$211M Market Cap

0.6x Rel. Volume

On the day this news was published, ABOS gained 0.30%, reflecting a mild positive market reaction. Argus tracked a peak move of +7.6% during that session. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $632K to the company's valuation, bringing the market cap to $211M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Event date: March 18, 2026 Event time: 11:00 a.m. ET Webcast archive period: 90 days

3 metrics

Event date March 18, 2026 Stifel 2026 Virtual CNS Forum fireside chat

Event time 11:00 a.m. ET Scheduled start of fireside chat webcast

Webcast archive period 90 days Duration webcast will remain available to investors

Market Reality Check

Price: $3.27 Vol: Volume 306,026 is near th...

normal vol

$3.27 Last Close

Volume Volume 306,026 is near the 311,158 20-day average (relative volume 0.98). normal

Technical Price $3.14 is trading above the 200-day MA at $1.78, indicating a pre-existing uptrend before this news.

Peers on Argus

ABOS fell 5.14% while several peers moved higher, including CRVO (10.46%), IMUX ...

2 Up

ABOS fell 5.14% while several peers moved higher, including CRVO (10.46%), IMUX (4.17%), ATRA (16.99%), and OVID (13.23%). This divergence points to company-specific trading rather than a pure sector move.

Common Catalyst Broader biotechnology strength with at least one peer (IMUX) posting IP-related news alongside general CNS/biotech momentum.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Conference presentations	Positive	+0.3%	AD/PD 2026 data on sabirnetug delivery, biomarkers, and new antibodies.
Dec 02	Clinical data update	Positive	-7.9%	CTAD data on brain delivery gains and ALTITUDE-AD recruitment metrics.
Nov 17	Clinical trial milestone	Positive	-8.7%	First participant dosed in Phase 2 open-label extension of sabirnetug.
Nov 12	Earnings and update	Neutral	-1.0%	Q3 2025 financials, cash runway into early 2027, program timelines.
Nov 10	Leadership change	Positive	+0.5%	Appointment of experienced biopharma executive as board chairman.

Pattern Detected

Recent positive and neutral news often saw muted or negative next-day price reactions, suggesting a tendency for the stock to fade good news.

Recent Company History

Over the last several months, Acumen reported multiple developments around its Alzheimer’s programs and corporate updates. Conference presentations in March 2026 and at CTAD in December 2025 highlighted Enhanced Brain Delivery and ALTITUDE-AD recruitment. Clinical progress included first dosing in a Phase 2 open-label extension announced on Nov. 17, 2025. Q3 2025 earnings on Nov. 12, 2025 detailed $136.1M in cash and R&D spending of $22.0M. A new board chairman was appointed on Nov. 10, 2025. Today’s conference participation fits this pattern of ongoing visibility-building news.

Market Pulse Summary

This announcement highlights Acumen’s participation in a Stifel CNS forum, extending its visibility ...

Analysis

This announcement highlights Acumen’s participation in a Stifel CNS forum, extending its visibility with a fireside chat on March 18, 2026. It follows prior conference and clinical updates on sabirnetug and Enhanced Brain Delivery over late 2025 and early 2026. Investors tracking the story may focus on future milestones like Phase 2 ALTITUDE-AD readouts and additional data disclosures, while recognizing that conference appearances themselves typically serve as communication events rather than fundamental inflection points.

Key Terms

clinical-stage biopharmaceutical, amyloid beta oligomers, webcast

3 terms

clinical-stage biopharmaceutical medical

"a clinical-stage biopharmaceutical company developing novel therapeutics..."

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

amyloid beta oligomers medical

"therapeutics that target toxic soluble amyloid beta oligomers for the treatment..."

Small, soluble clumps of a brain protein called amyloid beta that can interfere with nerve cell function and are suspected to drive memory loss in neurodegenerative disease. Investors watch them because drugs that reduce or neutralize these oligomers are a major focus of research, and convincing evidence that a treatment affects them can sway clinical trial success, regulatory decisions and a company’s valuation — like finding the right lock-and-key to stop engine damage.

webcast technical

"The live webcast may be accessed under the Investors tab..."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026, at 11:00 a.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE^® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.   

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 

FAQ

When will Acumen Pharmaceuticals (ABOS) present at the Stifel 2026 Virtual CNS Forum?

Acumen will present on Wednesday, March 18, 2026 at 11:00 a.m. ET. According to the company, management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum and the session will be webcast live.

How can investors watch the ABOS fireside chat from the Stifel 2026 Virtual CNS Forum?

Investors can watch via the company investor website under the Investors tab with a live webcast link. According to the company, the webcast will also be archived on the site for 90 days after the event.

Will the Acumen (ABOS) Stifel webcast be available after March 18, 2026?

Yes. The webcast will be archived for 90 days following the live event. According to the company, the archived presentation can be accessed under the Investors tab on the company website during that 90-day period.

What will Acumen Pharmaceuticals (ABOS) management likely discuss at the Stifel 2026 Virtual CNS Forum?

Management will participate in a fireside chat focused on the company’s clinical-stage programs for Alzheimer’s disease. According to the company, the discussion will cover its approach targeting toxic soluble amyloid beta oligomers and development progress.